Design Therapeutics, Inc. DSGN
Set alert
10.68 USD -0.38 -3.44%
At close
10.70 +0.02 +0.19%
Pre-market · Nov 2, 6:25 AM ET
10.51 Day range 11.13
6.16 52-week range 17.25
- YTD
- +13.86%
- 1 year
- +63.55%
- Open
- 10.96
- Prev close
- 11.06
- Mkt cap
- 668.37M
- Vol
- 199.25K
- Avg vol
- 585.09K
- EPS
- -1.18
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.51
- High
- 11.13
- Forward P/E
- -5.13
- Beta
- 1.83
- Short ratio
- 19.61
- Inst. own
- 56.85%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 5, 2024
- 50-d avg
- 5.88
- 200-d avg
- 4.63
- 1y target
- 7.00
Financial health
Altman Z-Score
28.04 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 2
Valuation
P/E -7.7×
FY 2019 5y median -7.7× FY 2025
P/S 0.0×
FY 2019 5y median 0.0× FY 2025
P/B 2.5×
FY 2019 5y median 1.7× FY 2025
P/FCF -9.9×
FY 2019 5y median -9.9× FY 2025
EV/EBITDA -7.6×
FY 2019 5y median -7.6× FY 2025
EV/Sales 0.0×
FY 2019 5y median 0.0× FY 2025
FCF Yield -10.1%
FY 2019 5y median -10.1% FY 2025
Profitability
Gross Margin 0.0%
FY 2019 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2019 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2019 5y median 0.0% FY 2025
ROE -32.8%
FY 2019 5y median -20.5% FY 2025
ROIC -37.1%
FY 2019 5y median -25.5% FY 2025
ROA -30.9%
FY 2019 5y median -19.7% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2019 FY 2025
Operating Income -27.4%
FY 2019 FY 2025
EPS (diluted) -38.6%
FY 2019 FY 2025
Free Cash Flow -25.6%
FY 2019 FY 2025
Financial Health
Current Ratio 17.1×
FY 2019 5y median 29.6× FY 2025
Quick Ratio 17.1×
FY 2019 5y median 29.6× FY 2025
Debt / Equity 0.0×
FY 2019 5y median 0.0× FY 2025
Net Debt / EBITDA 0.2×
FY 2019 5y median 0.4× FY 2025
Interest Coverage 0.0×
FY 2019 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2019 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2019 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31